Skip to main content
Erschienen in: Breast Cancer 4/2020

13.02.2020 | Original Article

Breast cancer risk prediction models and subsequent tumor characteristics

verfasst von: Eric A. Miller, Paul F. Pinsky, Brandy M. Heckman-Stoddard, Lori M. Minasian

Erschienen in: Breast Cancer | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

A previous study found evidence that a breast cancer risk prediction model preferentially selected for less aggressive tumors in Swedish women. In the US, the Gail model has been widely used and was used for entry criteria in two large breast cancer prevention trials. We assessed if higher risk levels from the Gail model were associated with less aggressive tumor characteristics and if risk levels were predictive of mortality and survival.

Methods

We used questionnaire data from women in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial to calculate Gail risk levels (low < 1.66%; moderate 1.66–2.99%; high ≥ 3.00%). Women aged 55–74 were enrolled between 1993 and 2001 and had detailed information on breast cancer incidence and tumors collected. We calculated breast cancer incidence and mortality rates among all women by risk levels and examined breast cancer survival and tumor characteristics among women diagnosed with breast cancer. We used Chi-squared tests and multivariable logistic regression to assess the association between risk levels and tumor characteristics.

Results

The study population for this analysis included 45,402 women with 1908 cases of breast cancer. Women at high risk were associated with higher risk of breast cancer mortality compared to women with low risk [rate ratio (RR) = 2.29 95% confidence interval (CI) 1.37–3.84)]. Higher risk levels were associated with lobular-type tumors [moderate: adjusted odds ratio (aOR) = 1.57 95% CI 1.13–2.17; high: aOR = 1.78 95% CI 1.25–2.54] but were not associated with any other tumor characteristics or breast cancer survival.

Conclusions

We did not find evidence that higher risk levels from the Gail model are predictive of less aggressive breast cancer tumors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.CrossRef Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.CrossRef
2.
Zurück zum Zitat Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, La Croix AZ, et al. Projecting individualized absolute invasive breast cancer risk in US hispanic women. J Natl Cancer Inst. 2017;109(2):djw215.CrossRef Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, La Croix AZ, et al. Projecting individualized absolute invasive breast cancer risk in US hispanic women. J Natl Cancer Inst. 2017;109(2):djw215.CrossRef
3.
Zurück zum Zitat Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541–8.CrossRef Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541–8.CrossRef
4.
Zurück zum Zitat Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, et al. Projecting individualized absolute invasive breast cancer risk in African–American women. J Natl Cancer Inst. 2007;99(23):1782–92.CrossRef Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, et al. Projecting individualized absolute invasive breast cancer risk in African–American women. J Natl Cancer Inst. 2007;99(23):1782–92.CrossRef
5.
Zurück zum Zitat Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951–61.CrossRef Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951–61.CrossRef
6.
Zurück zum Zitat Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA, et al. Validation of the Gail model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.CrossRef Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA, et al. Validation of the Gail model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.CrossRef
7.
Zurück zum Zitat Holm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, et al. Associations of breast cancer risk prediction tools with tumor characteristics and metastasis. J Clin Oncol. 2016;34(3):251–8.CrossRef Holm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, et al. Associations of breast cancer risk prediction tools with tumor characteristics and metastasis. J Clin Oncol. 2016;34(3):251–8.CrossRef
9.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.CrossRef Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.CrossRef
10.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.CrossRef Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.CrossRef
11.
Zurück zum Zitat Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):273S–309S.CrossRef Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):273S–309S.CrossRef
12.
Zurück zum Zitat Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255–66.CrossRef Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255–66.CrossRef
13.
Zurück zum Zitat Moyer VA, Force USPST. Medications to decrease the risk for breast cancer in women: recommendations from the US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(10):698–708.PubMed Moyer VA, Force USPST. Medications to decrease the risk for breast cancer in women: recommendations from the US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(10):698–708.PubMed
14.
Zurück zum Zitat Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.CrossRef Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.CrossRef
15.
Zurück zum Zitat Tartter PI, Gajdos C, Rosenbaum Smith S, Estabrook A, Rademaker AW. The prognostic significance of Gail model risk factors for women with breast cancer. Am J Surg. 2002;184(1):11–5.CrossRef Tartter PI, Gajdos C, Rosenbaum Smith S, Estabrook A, Rademaker AW. The prognostic significance of Gail model risk factors for women with breast cancer. Am J Surg. 2002;184(1):11–5.CrossRef
16.
Zurück zum Zitat Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA. Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res. 2010;12(6):R106.CrossRef Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA. Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res. 2010;12(6):R106.CrossRef
19.
Zurück zum Zitat Ritte R, Lukanova A, Berrino F, Dossus L, Tjonneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012;14(3):R76.CrossRef Ritte R, Lukanova A, Berrino F, Dossus L, Tjonneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012;14(3):R76.CrossRef
20.
Zurück zum Zitat Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114–36.CrossRef Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114–36.CrossRef
21.
Zurück zum Zitat Nattenmuller CJ, Kriegsmann M, Sookthai D, Fortner RT, Steffen A, Walter B, et al. Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer. 2018;18(1):616.CrossRef Nattenmuller CJ, Kriegsmann M, Sookthai D, Fortner RT, Steffen A, Walter B, et al. Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer. 2018;18(1):616.CrossRef
22.
Zurück zum Zitat Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007;165(8):874–81.CrossRef Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007;165(8):874–81.CrossRef
23.
Zurück zum Zitat Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med. 2006;8(9):571–5.CrossRef Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med. 2006;8(9):571–5.CrossRef
Metadaten
Titel
Breast cancer risk prediction models and subsequent tumor characteristics
verfasst von
Eric A. Miller
Paul F. Pinsky
Brandy M. Heckman-Stoddard
Lori M. Minasian
Publikationsdatum
13.02.2020
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2020
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01060-9

Weitere Artikel der Ausgabe 4/2020

Breast Cancer 4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.